334 related articles for article (PubMed ID: 31836930)
21. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Rafia R; Scope A; Harnan S; Stevens JW; Stevenson M; Lobo A
Pharmacoeconomics; 2016 Dec; 34(12):1241-1253. PubMed ID: 27480631
[TBL] [Abstract][Full Text] [Related]
22. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
Watanabe M; Hibi T; Lomax KG; Paulson SK; Chao J; Alam MS; Camez A;
J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
[TBL] [Abstract][Full Text] [Related]
24. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
26. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
[TBL] [Abstract][Full Text] [Related]
28. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
29. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Targan SR; Feagan B; Vermeire S; Panaccione R; Melmed GY; Landers C; Li D; Russell C; Newmark R; Zhang N; Chon Y; Hsu YH; Lin SL; Klekotka P
Am J Gastroenterol; 2016 Nov; 111(11):1599-1607. PubMed ID: 27481309
[TBL] [Abstract][Full Text] [Related]
30. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.
Nagahori M; Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Pinton P; Ursos L; Sakamoto S; Shikamura M; Hori T; Fernandez J; Hibi T; Watanabe M
Digestion; 2021; 102(5):742-752. PubMed ID: 33454706
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
33. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
37. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
[TBL] [Abstract][Full Text] [Related]
39. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
Reinisch W; de Villiers W; Bene L; Simon L; Rácz I; Katz S; Altorjay I; Feagan B; Riff D; Bernstein CN; Hommes D; Rutgeerts P; Cortot A; Gaspari M; Cheng M; Pearce T; Sands BE
Inflamm Bowel Dis; 2010 Feb; 16(2):233-42. PubMed ID: 19637334
[TBL] [Abstract][Full Text] [Related]
40. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
